Literature DB >> 31356277

New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis.

Xu-Feng Zhang1,2, Feng Xue1, Ding-Hui Dong1, Alexandra G Lopez-Aguiar3, George Poultsides4, Eleftherios Makris4, Flavio Rocha5, Zaheer Kanji5, Sharon Weber6, Alexander Fisher6, Ryan Fields7, Bradley A Krasnick7, Kamran Idrees8, Paula M Smith8, Cliff Cho9, Megan Beems9, Yi Lv1, Shishir K Maithel3, Timothy M Pawlik2.   

Abstract

OBJECTIVE: To determine the prognostic role of metastatic lymph node (LN) number and the minimal number of LNs for optimal staging of patients with pancreatic neuroendocrine tumors (pNETs).
BACKGROUND: Prognosis relative to number of LN metastasis (LNM), and minimal number of LNs needed to evaluate for accurate staging, have been poorly defined for pNETs.
METHODS: Number of LNM and total number of LN evaluated (TNLE) were assessed relative to recurrence-free survival (RFS) and overall survival (OS) in a multi-institutional database. External validation was performed using Surveillance, Epidemiology and End Results (SEER) registry.
RESULTS: Among 854 patients who underwent resection, 233 (27.3%) had at least 1 LNM. Patients with 1, 2, or 3 LNM had a comparable worse RFS versus patients with no nodal metastasis (5-year RFS, 1 LNM 65.6%, 2 LNM 68.2%, 3 LNM 63.2% vs 0 LNM 82.6%; all P < 0.001). In contrast, patients with ≥4 LNM (proposed N2) had a worse RFS versus patients who either had 1 to 3 LNM (proposed N1) or node-negative disease (5-year RFS, ≥4 LNM 43.5% vs 1-3 LNM 66.3%, 0 LNM 82.6%; all P < 0.05) [C-statistics area under the curve (AUC) 0.650]. TNLE ≥8 had the highest discriminatory power relative to RFS (AUC 0.713) and OS (AUC 0.726) among patients who had 1 to 3 LNM, and patients who had ≥4 LNM in the multi-institutional and SEER database (n = 2764).
CONCLUSIONS: Regional lymphadenectomy of at least 8 lymph nodes was necessary to stage patients accurately. The proposed nodal staging of N0, N1, and N2 optimally staged patients.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 31356277     DOI: 10.1097/SLA.0000000000003478

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms.

Authors:  Pin Zhang; Zhiwen Xiao; Huaxiang Xu; Xinzhe Zhu; Lei Wang; Dan Huang; Yun Liang; Quanxing Ni; Jie Chen; Xianjun Yu; Guopei Luo
Journal:  Endocrine       Date:  2022-07-05       Impact factor: 3.925

2.  Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based study.

Authors:  Nian Guo; Zhen Liang; Li Jiao Xiong
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

3.  Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.

Authors:  Jaseela Chiramel; Rose Almond; Astrid Slagter; Adeel Khan; Xin Wang; Kok Haw Jonathan Lim; Melissa Frizziero; Bipasha Chakrabarty; Annamaria Minicozzi; Angela Lamarca; Wasat Mansoor; Richard A Hubner; Juan William Valle; Mairéad Geraldine McNamara
Journal:  World J Clin Oncol       Date:  2020-04-24

4.  Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery.

Authors:  Linzhi Gao; Jun Lyu; Xiaoya Luo; Dong Zhang; Guifang Jiang; Xian Zhang; Xuesong Gao; Shaolie Zheng; Xiaoyu Wang; Yuan Shen
Journal:  BMC Cancer       Date:  2021-10-27       Impact factor: 4.430

5.  Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.

Authors:  Alessandro Vanoli; Oneda Grami; Catherine Klersy; Anna Caterina Milanetto; Luca Albarello; Matteo Fassan; Claudio Luchini; Federica Grillo; Paola Spaggiari; Frediano Inzani; Silvia Uccella; Paola Parente; Gennaro Nappo; Paola Mattiolo; Massimo Milione; Andrea Pietrabissa; Lorenzo Cobianchi; Marco Schiavo Lena; Stefano Partelli; Antonio Di Sabatino; Christine Sempoux; Carlo Capella; Claudio Pasquali; Claudio Doglioni; Fausto Sessa; Aldo Scarpa; Guido Rindi; Marco Paulli; Alessandro Zerbi; Massimo Falconi; Enrico Solcia; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2022-05-13       Impact factor: 4.056

6.  Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study.

Authors:  Qingquan Tan; Xing Wang; Yichen Li; Yingyi Liu; Xubao Liu; Nengwen Ke
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

7.  Development and external validation of a dynamic nomogram to predict the survival for adenosquamous carcinoma of the pancreas.

Authors:  Chao Ren; Yifei Ma; Jiabin Jin; Jiachun Ding; Yina Jiang; Yinying Wu; Wei Li; Xue Yang; Liang Han; Qingyong Ma; Zheng Wu; Yusheng Shi; Zheng Wang
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

8.  Values of spleen-preserving distal pancreatectomy in well-differentiated non-functioning pancreatic neuroendocrine tumors: a comparative study.

Authors:  Xi-Tai Huang; Jin-Zhao Xie; Jian-Peng Cai; Peng Fang; Chen-Song Huang; Wei Chen; Li-Jian Liang; Xiao-Yu Yin
Journal:  Gastroenterol Rep (Oxf)       Date:  2022-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.